Co-Administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM

Abstract

Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental part of the management of type 2 DM and difficult to achieve. Different antidiabetic agents can handle diabetic metabolic abnormalities. The development of antidiabetic agents with novel mechanisms of action is highly desirable. Cabergoline, D2 agonist, is expected to play a role in the glycemic control. Objective: Evaluation of the glycemic efficacy of cabergoline on diabetic patients. Design: Fifty type 2 diabetic patients participated in the study for four months; 25 patients receive gliclazide (60-120 mg) once daily and 25 patients receive cabergoline 0.5 mg twice weekly within 2 hrs of wakening plus gliclazide. 10 healthy people with matched age participated as a control group. Fasting and post prandial BG level were measuredmonthly. HbA1c, fasting insulin, HOMA IR and lipid profile were measured at baseline and after four months. Results: Treatment of the patients with cabergoline and gliclazide resulted in greater significant (p<0.05) decrease in FBG, PPBG, HbA1c compared treatment with gliclazide only. Insulin levels were reduced and insulin sensitivity was enhanced with improvement in lipid profile. Conclusion: Cabergoline is well-tolerated new antidiabetic line acting with a unique insulin sensitizing actions.